Mikhail Blagosklonny is a renowned oncology professor and cancer scientist that has accomplished many feats in his profession. He created a hypothesis specializing on TOR and its role in cancer and aging. Blagosklonny has carried out extensive research on rapamycin, which is a cancer medicine, and its ability to be used as an anti-aging therapy.
Notably, the professor of oncology’s research focuses on the potential cancer remedies. It also zeroes in on the principal methods of anti-age medication. Blagosklonny is one of the staunch supporters of the use of rapamycin in the area of longevity research. He points out that the popular cancer drug has the potential to treat aging-related illnesses.
According to Impact Journals, Mikhail has a sound educational background. He earned his M.D. in internal medicine from Pavlov State Medical University. Later, he pursued his PhD in experimental medicine and cardiology from the same institution. In 2002, Mikhail Blagosklonny was appointed by the New York Medical College to serve as an associate professor of medicine.
Subsequently, he became a senior scientist at New York’s Ordway Research Institute until 2009 when Roswell Park Cancer Institute appointed him to work as the professor of oncology. His LinkedIn profile shows us that at Roswell, Mikhail Blagosklonny was a principal researcher in the expansion of cancer concepts, particularly in biology and therapy.
In addition, Mikhail Blagosklonny has many publications to his name. His publications, which include 270 papers, have enabled him to acquire an h-index of 83. They have been published in peer-reviewed journals and widely read.
His papers have more than 25,000 citations. Samples of his titles include Oncogenic Resistance to Growth-limiting Conditions and Matching Targets for Selective Cancer Therapy. Blagosklonny is also the author of Unwinding the Loop of Bcl-2 Phosphorylation as well as Hypoxia, MTOR and Autophagy: Converging on Senescence or Quiescence.
Additionally, Mikhail Blagosklonny edits several publications, especially where he serves as the editor in chief, member of the editorial board, or associate editor. These publications consist of Oncotarget, Cancer Biology & Therapy, Cell Cycle, Cell Death & Differentiation, as well as Aging.